ANSWER: C

Rationale:

This patient has taken prednisone 15 mg daily for 8 months — well above the threshold and duration for substantial HPA axis suppression. Her adrenal glands cannot mount an adequate cortisol stress response to the major physiological stress of surgery, and the inadvertent omission of her glucocorticoid has precipitated an adrenal crisis: refractory hypotension disproportionate to apparent cause, nausea, and hyponatremia. The immediate, life-saving intervention is intravenous stress-dose hydrocortisone. Hydrocortisone is preferred in adrenal crisis because it provides both glucocorticoid and, at stress doses, sufficient mineralocorticoid activity, and it acts rapidly. Recognition that perioperative hypotension refractory to fluids and pressors in a chronically steroid-dependent patient represents adrenal crisis — not occult hemorrhage or anesthetic effect — is the central clinical reasoning point.

• Option A: Option A is incorrect because escalating vasopressors and fluids alone will not correct hypotension caused by glucocorticoid deficiency; cortisol is required to restore vascular responsiveness to catecholamines. Attributing the picture to anesthetic vasodilation overlooks the patient's chronic steroid dependence and the classic adrenal crisis presentation, and delays the only effective treatment.
• Option B: Option B is incorrect because, while pulmonary embolism is a consideration in perioperative hypotension, this patient's chronic high-dose steroid history, hyponatremia, nausea, and fluid/pressor-refractory hypotension point clearly to adrenal crisis. Pursuing CT angiography before administering stress-dose hydrocortisone would dangerously delay treatment of a rapidly life-threatening, easily reversible condition.
• Option D: Option D is incorrect because the priority in adrenal crisis is immediate treatment, not diagnostic preservation of a cortisol assay. While dexamethasone does not cross-react with cortisol assays, withholding hydrocortisone to facilitate testing in a hemodynamically unstable patient is inappropriate; treatment must not be deferred for diagnostic convenience. Hydrocortisone is the agent of choice in crisis.
• Option E: Option E is incorrect because the hyponatremia in this setting reflects glucocorticoid deficiency (cortisol deficiency impairs free-water excretion and reduces vascular tone), not isolated mineralocorticoid deficiency. Fludrocortisone alone is inadequate and slow; the patient requires immediate hydrocortisone to treat the glucocorticoid-deficient adrenal crisis.

ANSWER: A

Rationale:

This neonate has the classic salt-wasting presentation of 21-hydroxylase (CYP21A2) deficiency, the cause of more than 90% of congenital adrenal hyperplasia. The enzyme block impairs both cortisol and aldosterone synthesis; the markedly elevated 17-OHP (the substrate immediately proximal to the block) is diagnostic, and the accumulated 17-OHP is shunted toward androgen synthesis, producing virilization (clitoromegaly in a female infant). Aldosterone deficiency produces salt-wasting with hyponatremia and hyperkalemia, and cortisol deficiency contributes to hypoglycemia and poor stress tolerance. Treatment is glucocorticoid replacement (hydrocortisone), which restores cortisol and, importantly, suppresses the elevated ACTH drive that fuels androgen overproduction, combined with mineralocorticoid replacement (fludrocortisone) and sodium supplementation to correct the salt-wasting. The dual rationale — replacing cortisol and suppressing ACTH-driven androgen excess — is the key reasoning point.

• Option B: Option B is incorrect because 11β-hydroxylase (CYP11B1) deficiency produces hypertension from 11-deoxycorticosterone accumulation, not salt-wasting with hyponatremia and hyperkalemia. The diagnostic marker would not be elevated 17-OHP to this degree, and this infant's salt-wasting electrolyte pattern is incompatible with the hypertensive form.
• Option C: Option C is incorrect because 17α-hydroxylase (CYP17A1) deficiency causes absent virilization (not clitoromegaly) and hypertension from mineralocorticoid precursor accumulation, and would not produce salt-wasting or elevated 17-OHP. This infant's virilization and salt-wasting are inconsistent with CYP17A1 deficiency, and mineralocorticoid replacement is needed here, not withheld.
• Option D: Option D is incorrect because aldosterone synthase (CYP11B2) deficiency impairs only aldosterone synthesis with normal cortisol and androgens — it would not cause virilization or elevated 17-OHP. While salt-wasting occurs, the presence of clitoromegaly and markedly elevated 17-OHP points to 21-hydroxylase deficiency requiring both glucocorticoid and mineralocorticoid replacement, not isolated fludrocortisone.
• Option E: Option E is incorrect because StAR protein deficiency (congenital lipoid adrenal hyperplasia) causes near-total failure of all steroidogenesis with severe salt-wasting and is life-threatening, not self-limited. It would not produce elevated 17-OHP (the block is upstream of all synthesis), and it absolutely requires glucocorticoid and mineralocorticoid replacement rather than supportive hydration alone.

ANSWER: D

Rationale:

This is a classic and clinically important drug interaction. Fluticasone propionate is extensively metabolized by CYP3A4 (cytochrome P450 3A4). Ritonavir is one of the most potent CYP3A4 inhibitors in clinical use. When the two are combined, ritonavir blocks the metabolism of fluticasone, dramatically increasing systemic fluticasone exposure — even from inhaled dosing that would normally produce minimal systemic effect. The result is iatrogenic Cushing syndrome from exogenous glucocorticoid excess: moon facies, central adiposity, and easy bruising. The high systemic fluticasone level simultaneously suppresses the HPA axis, which is why the patient's endogenous morning cortisol is undetectable — the exogenous steroid is providing (and exceeding) the body's glucocorticoid needs while shutting down endogenous production. Recognizing that the Cushingoid features and suppressed cortisol coexist because of CYP3A4 inhibition is the central reasoning point.

• Option A: Option A is incorrect because ritonavir inhibits CYP3A4, it does not induce it. Inhibition increases fluticasone exposure, producing glucocorticoid excess (Cushingoid features), not deficiency. The picture is iatrogenic Cushing syndrome, not steroid withdrawal.
• Option B: Option B is incorrect because the undetectable morning cortisol reflects HPA suppression from systemic glucocorticoid excess, not primary adrenal failure from ritonavir toxicity. The Cushingoid features indicate excess exogenous glucocorticoid, which is directly related to the fluticasone–ritonavir interaction, not adrenal cortex destruction.
• Option C: Option C is incorrect because, although inhaled fluticasone normally produces minimal systemic effect, CYP3A4 inhibition by ritonavir substantially increases its systemic exposure, making clinically significant Cushing syndrome possible from inhaled dosing. The picture is explained by the drug interaction, not an independent ACTH-secreting tumor (which would raise, not suppress, ACTH-driven cortisol).
• Option E: Option E is incorrect because inhaled corticosteroids and oral protease inhibitors do interact systemically: absorbed fluticasone enters the circulation and is metabolized by hepatic and intestinal CYP3A4, the same enzyme inhibited by ritonavir. The anatomic route of administration does not prevent a systemic pharmacokinetic interaction.

ANSWER: B

Rationale:

This patient depends entirely on exogenous hydrocortisone for her cortisol because of secondary adrenal insufficiency. Rifampin is one of the most potent CYP3A4 (cytochrome P450 3A4) inducers in clinical use, and glucocorticoids are metabolized primarily by CYP3A4. Starting rifampin upregulates CYP3A4 over 1 to 2 weeks, accelerating hydrocortisone clearance and reducing plasma cortisol — which precipitates relative adrenal insufficiency in a replacement-dependent patient. Her fatigue, anorexia, nausea, and orthostatic hypotension are the expected clinical manifestations. The correct management is to substantially increase the hydrocortisone replacement dose for the duration of rifampin therapy (often roughly doubling it), with the dose tapered back when rifampin is stopped. Recognizing that an enzyme-inducing drug lowers glucocorticoid exposure in a dependent patient — requiring a dose increase, not a decrease — is the central reasoning point.

• Option A: Option A is incorrect because rifampin's effect here is CYP3A4 induction lowering cortisol, not hepatotoxicity raising it. The symptoms are those of glucocorticoid deficiency, not Cushingoid excess, so decreasing the hydrocortisone dose would worsen the crisis.
• Option C: Option C is incorrect because rifampin does not displace cortisol from CBG (corticosteroid-binding globulin) or increase renal cortisol clearance through protein-binding competition. The mechanism is hepatic CYP3A4 induction accelerating metabolism. Adding fludrocortisone does not address the accelerated glucocorticoid clearance; the hydrocortisone dose must be increased.
• Option D: Option D is incorrect because rifampin does not destroy the adrenal glands. The patient's deterioration is due to accelerated hydrocortisone metabolism from CYP3A4 induction, not new primary adrenal destruction. Leaving hydrocortisone unchanged would fail to correct the relative deficiency the induction has produced.
• Option E: Option E is incorrect because rifampin induces CYP3A4 rather than inhibiting it, so it lowers — not raises — hydrocortisone levels. The symptoms reflect glucocorticoid deficiency, not excess; discontinuing hydrocortisone would be dangerous and could precipitate frank adrenal crisis.

ANSWER: E

Rationale:

Metyrapone inhibits CYP11B1 (11β-hydroxylase), the enzyme that converts 11-deoxycortisol to cortisol. The expected, on-target biochemical effect is therefore a fall in plasma cortisol (the product distal to the block) together with a rise in 11-deoxycortisol (the substrate that accumulates proximal to the block). In ACTH-dependent Cushing syndrome, the falling cortisol may also relieve negative feedback and allow ACTH to rise, which can partially drive steroidogenesis and further increase 11-deoxycortisol — one reason metyrapone monotherapy may require dose escalation or combination therapy. The intended therapeutic benefit is the reduction in cortisol; the rise in 11-deoxycortisol is the expected biochemical signature of CYP11B1 blockade. Recognizing this substrate-accumulation/product-depletion pattern is the key reasoning point.

• Option A: Option A is incorrect because metyrapone inhibits CYP11B1, so cortisol falls and 11-deoxycortisol rises — the opposite of the pattern described. Metyrapone does not enhance CYP11B1 activity.
• Option B: Option B is incorrect because metyrapone acts at the CYP11B1 step, not at StAR-mediated cholesterol transport, so it does not globally suppress all steroidogenesis. 11-deoxycortisol rises (it accumulates proximal to the block) rather than falling, and ACTH tends to rise rather than fall as cortisol declines.
• Option C: Option C is incorrect because metyrapone does not selectively stimulate CYP11B2 or raise aldosterone; its principal action is CYP11B1 inhibition reducing cortisol. Aldosterone is not the expected on-target readout of metyrapone therapy.
• Option D: Option D is incorrect because metyrapone inhibits CYP11B1, not CYP21A2, so the accumulating substrate is 11-deoxycortisol (proximal to CYP11B1), not 17-OHP (proximal to CYP21A2). Cortisol does change — it falls — rather than remaining unchanged.

ANSWER: C

Rationale:

This patient needs effective systemic anti-inflammatory therapy but has hypertension, peripheral edema, and chronic kidney disease — all conditions that would be worsened by glucocorticoid-associated sodium and fluid retention. Methylprednisolone is the most appropriate choice because it delivers good anti-inflammatory potency (approximately 5 times that of hydrocortisone) while having negligible mineralocorticoid activity, so it does not meaningfully promote sodium retention. This minimizes the risk of worsening his blood pressure, edema, and volume status. The clinical reasoning is to match anti-inflammatory efficacy with the lowest mineralocorticoid burden in a patient whose comorbidities are sensitive to sodium retention.

• Option A: Option A is incorrect because hydrocortisone has high mineralocorticoid activity — the greatest among commonly used systemic glucocorticoids — and would promote sodium and fluid retention that worsens hypertension and edema. Its short half-life does not offset its inherent sodium-retaining activity at anti-inflammatory doses.
• Option B: Option B is incorrect because fludrocortisone is a potent mineralocorticoid used specifically to promote sodium retention (for example in primary adrenal insufficiency or orthostatic hypotension). In a patient with hypertension and edema, its sodium-retaining effect is exactly what must be avoided, and it is not used as a systemic anti-inflammatory agent.
• Option D: Option D is incorrect because prednisone's moderate mineralocorticoid activity (approximately 0.8 times that of hydrocortisone) is undesirable here — sodium retention would worsen hypertension and edema in this patient. Maintaining blood pressure through mineralocorticoid-mediated volume expansion is not a therapeutic goal in someone who is already hypertensive and edematous.
• Option E: Option E is incorrect because cortisone acetate is converted to cortisol (hydrocortisone), which has high mineralocorticoid activity; it would promote sodium retention rather than being a low-mineralocorticoid choice. Volume expansion is harmful, not helpful, in this edematous, hypertensive patient.

ANSWER: B

Rationale:

Prednisone is an inactive prodrug that must be converted to its active form, prednisolone, by hepatic 11β-HSD1 (11 beta-hydroxysteroid dehydrogenase type 1). In a patient with normal liver function this conversion is rapid and nearly complete, making prednisone and prednisolone interchangeable. In decompensated cirrhosis, however, impaired 11β-HSD1 activity reduces the generation of active prednisolone, so a patient may fail to respond despite adequate prednisone dosing and good adherence. The appropriate intervention is to switch to prednisolone, which is administered as the active drug and therefore bypasses the failing hepatic activation step, ensuring reliable delivery of active glucocorticoid. Recognizing that nonresponse in cirrhosis can reflect impaired prodrug activation — correctable by giving the active form — is the central reasoning point.

• Option A: Option A is incorrect because the problem is impaired activation of the prodrug, not simply underdosing, and cirrhosis tends to impair (not accelerate) hepatic drug handling. Escalating the dose of an inadequately activated prodrug is an unreliable strategy; switching to the active form (prednisolone) directly addresses the mechanism.
• Option C: Option C is incorrect because dexamethasone is not eliminated entirely by the kidney — it is metabolized hepatically by CYP3A4 like other glucocorticoids. While dexamethasone does not require 11β-HSD1 activation, the standard and sufficient solution for impaired prednisone activation is to switch to prednisolone, the active form of the same drug; the claim that dexamethasone requires no hepatic handling is incorrect.
• Option D: Option D is incorrect because rifampin induces CYP3A4, which would accelerate clearance of prednisolone and reduce active drug exposure — worsening, not improving, the response. Rifampin does not enhance the 11β-HSD1 activation of prednisone, and adding it would be counterproductive.
• Option E: Option E is incorrect because the nonresponse is most plausibly explained by impaired prodrug activation in cirrhosis, not by intrinsic glucocorticoid resistance. Switching to prednisolone is likely to restore efficacy, so discontinuing all glucocorticoids would inappropriately abandon effective therapy for autoimmune hepatitis.

ANSWER: D

Rationale:

This patient needs induction therapy for ileocecal Crohn disease with minimal systemic glucocorticoid exposure given her prior systemic side effects. Oral controlled-ileal-release budesonide is the appropriate choice. It is formulated to release drug at the distal ileum and proximal colon, delivering high local anti-inflammatory concentration to the affected mucosa. Absorbed drug then undergoes approximately 85 to 90 percent first-pass hepatic metabolism to inactive metabolites, limiting systemic bioavailability to roughly 10 to 15 percent. The result is effective local transrepression-mediated anti-inflammatory action with substantially less systemic transactivation-mediated adverse effect and less HPA suppression than equipotent prednisone. This is the pharmacokinetic basis for preferring budesonide over systemic prednisone for induction in mild-to-moderate ileocecal Crohn disease, and it directly addresses her concern about systemic side effects.

• Option A: Option A is incorrect because intravenous methylprednisolone is a fully systemic glucocorticoid; although it has negligible mineralocorticoid activity, it produces the full range of systemic glucocorticoid adverse effects (weight gain, mood changes, HPA suppression) that this patient wishes to avoid. It does not provide the local-delivery, systemic-sparing advantage of budesonide.
• Option B: Option B is incorrect because dexamethasone is a potent, long-acting systemic glucocorticoid that causes pronounced and sustained HPA suppression; once-weekly dosing is not a standard or effective induction strategy for Crohn disease, and it would not minimize systemic exposure. It lacks the targeted gut delivery this patient needs.
• Option C: Option C is incorrect because lowering the prednisone dose does not proportionally eliminate systemic side effects while preserving mucosal efficacy — systemic prednisone acts systemically regardless of dose, and reducing the dose to limit side effects would also reduce efficacy. Budesonide achieves the local-versus-systemic separation that simple dose reduction of prednisone cannot.
• Option E: Option E is incorrect because fludrocortisone is a mineralocorticoid used to promote sodium retention, not a treatment for intestinal inflammation. It has no role in inducing remission in Crohn disease and does not provide local anti-inflammatory action.

ANSWER: A

Rationale:

Morning plasma cortisol is interpreted in three zones for assessing HPA axis recovery: greater than 18 micrograms per deciliter indicates adequate recovery and low adrenal crisis risk; less than 3 micrograms per deciliter indicates persistent severe suppression; and values in between are indeterminate. This patient's value of 9 micrograms per deciliter falls squarely in the indeterminate range, so a basal measurement alone cannot establish whether his axis can mount an adequate stress response. The appropriate next step is dynamic testing — most practically the low-dose short Synacthen test (LDSST), in which 1 microgram of synthetic ACTH (tetracosactide) is given intravenously and cortisol is measured at 30 minutes, with a peak greater than 18 micrograms per deciliter considered normal. This characterizes the stress-response reserve before the final dose is discontinued. Correctly placing the value in the indeterminate zone and selecting dynamic testing is the key reasoning point.

• Option B: Option B is incorrect because 9 micrograms per deciliter does not indicate full recovery — the adequacy threshold is greater than 18 micrograms per deciliter. A value of 9 is indeterminate, and discontinuing glucocorticoids without dynamic testing could leave the patient unable to mount a cortisol response to subsequent stress, risking adrenal crisis.
• Option C: Option C is incorrect because 9 micrograms per deciliter does not indicate severe or permanent suppression — that would require a value below 3 micrograms per deciliter, and HPA recovery is generally not permanent in any case. Committing the patient to lifelong replacement based on an indeterminate value, without dynamic testing, is unwarranted.
• Option D: Option D is incorrect because a single morning cortisol can be interpreted within the three-zone framework, and dynamic testing IS indicated for indeterminate values. Averaging repeated basal measurements does not substitute for assessing stress-response capacity, which only a dynamic test can characterize.
• Option E: Option E is incorrect because administering dexamethasone and looking for suppression is the logic of the dexamethasone suppression test used to diagnose cortisol excess (Cushing syndrome), not to assess recovery of a suppressed axis. To evaluate HPA recovery, one stimulates the axis (with ACTH in the LDSST) and looks for an adequate cortisol rise, not suppression.

ANSWER: E

Rationale:

Dexamethasone is the standard glucocorticoid for reducing vasogenic edema around brain tumors, and the reasoning integrates three of its properties. First, it has very high anti-inflammatory potency (approximately 25 to 30 times that of hydrocortisone), allowing effective edema reduction at modest doses. Second, it has essentially no mineralocorticoid activity, so it does not promote the sodium and water retention that would raise intravascular volume and could worsen intracranial pressure — a critical consideration in a patient with midline shift. Third, its long biologic duration of action (36 to 54 hours) provides sustained effect with convenient dosing. These combined properties make dexamethasone the agent of choice for peritumoral cerebral edema, spinal cord compression, and other CNS (central nervous system) edema indications. Selecting the high-potency, mineralocorticoid-sparing, long-acting agent for cerebral edema is the central reasoning point.

• Option A: Option A is incorrect because hydrocortisone has high mineralocorticoid activity that promotes sodium and water retention — undesirable in a patient with raised intracranial pressure and midline shift. Volume expansion does not beneficially treat vasogenic edema and could worsen it; hydrocortisone's modest anti-inflammatory potency also makes it a poor choice here.
• Option B: Option B is incorrect because prednisolone has moderate mineralocorticoid activity (sodium retention is undesirable in cerebral edema) and lower anti-inflammatory potency (approximately 4-fold) than dexamethasone. It is not the standard agent for peritumoral brain edema.
• Option C: Option C is incorrect because fludrocortisone is a potent mineralocorticoid that promotes sodium and water retention; this would tend to worsen, not reduce, vasogenic edema and intracranial pressure. It has no role in treating cerebral edema.
• Option D: Option D is incorrect because methylprednisolone has only about 5-fold anti-inflammatory potency and negligible (not long-acting) mineralocorticoid activity, and once-weekly pulse dosing is not an appropriate regimen for controlling peritumoral cerebral edema. Dexamethasone, dosed daily or in divided doses, is the established choice.

ANSWER: C

Rationale:

This patient demonstrates clinical glucocorticoid resistance, and the elevated GR-beta is the mechanistic explanation. GR-beta is an alternatively spliced isoform that does not bind glucocorticoids and acts as a dominant-negative inhibitor of GR-alpha by competing for coactivators and DNA-binding sites. When GR-beta is markedly overexpressed relative to GR-alpha, it blunts the ligand-bound GR-alpha signaling that mediates the anti-inflammatory response, producing diminishing clinical benefit despite confirmed adherence, therapeutic drug levels, and no interacting drugs. The key clinical reasoning is to recognize that the diminishing response reflects a receptor-level resistance mechanism, not simple undertreatment — so indefinite dose escalation is both ineffective and harmful (it adds toxicity without benefit). Management should pivot toward steroid-sparing biologic or alternative anti-inflammatory strategies rather than continued dose increases.

• Option A: Option A is incorrect because glucocorticoids do not cause clinically significant CYP3A4 autoinduction that would explain escalating dose requirements, and drug levels are stated to be therapeutic. The explanation is GR-beta-mediated receptor resistance, not accelerated clearance, and continued dose escalation is not the appropriate solution.
• Option B: Option B is incorrect because the elevated GR-beta indicates a genuine receptor-level resistance mechanism, not mere undertreatment. With dominant-negative GR-beta overexpression, simply pushing the dose higher does not restore responsiveness and increases toxicity; the diminishing benefit is not an artifact of inadequate dosing.
• Option D: Option D is incorrect because GR-beta does not enhance glucocorticoid sensitivity — it acts as a dominant-negative inhibitor that reduces responsiveness. The elevated GR-beta directly explains the resistance through a receptor mechanism, rather than being unrelated to it.
• Option E: Option E is incorrect because the resistance results from dominant-negative GR-beta inhibition of GR-alpha, not from accelerated metabolism of GR-alpha protein. Adding a CYP3A4 inhibitor would raise systemic glucocorticoid levels (increasing toxicity) without addressing the GR-beta-mediated resistance, and CYP3A4 does not govern glucocorticoid receptor turnover.